Awarded €2.4m grant by EU’s Horizon 2020 framework
This highly competitive grant of €2.4 million was awarded to RSP Systems, to assist in the continued development of our non-invasive BGM device.
This grant is funded under the Horizon 2020 SME (Small and Medium-sized Enterprises) instrument, phase 2 by the EU. It lists under project number 738973. The project runs from March 2017 through to August 2019.
Stefan Ovesen Banke, founder, and CTO of RSP Systems A/S noted: Being awarded this grant is our reward for consistently focusing on the challenges of applying Raman Spectroscopy for the quantitation of analytes in living tissue. The last leg of the journey is to productize our prototype for market introduction as soon as possible. The Horizon grant is a noteworthy facilitator to achieve our goals. Due to the strict selection process, we have undergone, it is also a strong endorsement of our company and technology.
More about the SME instrument
The SME instrument is a financial flagship initiative funding innovative and potential SME projects. Hence, it globally promotes the competitiveness of the European Union. This initiative further encourages innovations, inventions and pioneering discoveries. With the help of the H2020 grant, RSP Systems can dedicate and unify multidisciplinary expertise in the development of the glucose device. Launching a truly non-invasive blood glucose monitoring device on the market will radically influence daily diabetes management strategies. Affecting millions of people worldwide, it will eventually create a major positive impact on screening methodologies and healthcare expenses.
To deliver necessary cardinal results, our project is organised into several specific activities which include optical technology, software development, clinical validation, marketing, and dissemination, as well as project management. RSP Systems will continuously strive to deliver state of the art technology and cutting-edge performance with a clear objective of delivering our breakthrough device to the market.